**Core Concept**
The question is testing the analgesic efficacy of various non-steroidal anti-inflammatory drugs (NSAIDs) and their ability to inhibit pain perception. This is based on the underlying pharmacological principle of cyclooxygenase (COX) enzyme inhibition, which affects prostaglandin synthesis and subsequently pain transmission.

**Why the Correct Answer is Right**
The correct answer is likely a NSAID that has a lower affinity for COX-1 or COX-2 enzymes, resulting in reduced inhibition of prostaglandin synthesis and therefore decreased analgesic efficacy. This is particularly relevant for NSAIDs that have a greater selectivity for COX-2, such as celecoxib, which may not adequately inhibit pain transmission.

**Why Each Wrong Option is Incorrect**
* **Option A:** This NSAID is known for its high COX-2 selectivity and potent analgesic effects, making it an unlikely candidate for the least analgesic option.
* **Option B:** While this NSAID has a relatively lower COX-2 selectivity compared to others, it is still a potent analgesic and is not the least effective option.
* **Option D:** This NSAID is known for its low COX-2 selectivity and potent COX-1 inhibition, which can lead to gastrointestinal side effects, but it is still an effective analgesic.

**Clinical Pearl / High-Yield Fact**
When choosing a NSAID for analgesia, clinicians should consider the balance between analgesic efficacy and gastrointestinal risk. Patients with a history of peptic ulcers or gastrointestinal bleeding may require a COX-2 selective NSAID or an alternative analgesic strategy.

**Correct Answer:** D.